sufentanil sublingual tablet 30 mcg
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Moderate-to-severe Pain
Conditions
Acute Moderate-to-severe Pain
Trial Timeline
Mar 1, 2016 → Jul 1, 2016
NCT ID
NCT02662556About sufentanil sublingual tablet 30 mcg
sufentanil sublingual tablet 30 mcg is a phase 3 stage product being developed by Talphera for Acute Moderate-to-severe Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02662556. Target conditions include Acute Moderate-to-severe Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02662556 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Moderate-to-severe Pain
Other Products from Talphera
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCAPhase 3
69
Zalviso™ 15 mcgPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69
sufentanil sublingual 30 mcg tabletPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69